RMD.NYSEResmed INC

Form 4: Resmed CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Michael J. Farrell, Chairman and CEO and a Director of Resmed Inc, sold 4,991 shares of common stock on August 7, 2026 for $205.69 per share.

Summary

  • Option exercise/conversion: acquired 4,991 ResMed Common Stock at $146.34 ($730,383) on August 7, 2026; holds 471,247 after (Direct).
  • Open-market sale: disposed of 4,991 ResMed Common Stock at $205.69 ($1,026,596) on August 7, 2026; holds 466,256 after (Direct).
  • Option exercise/conversion: disposed of 4,991 ResMed Common Stock Options on August 7, 2026; holds 14,975 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,026,596 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Michael J. Farrell — Director, Officer (Chairman and CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-07Option exercise/conversionResMed Common Stock4,991$146$730.4K471,247
2026-08-07Open-market saleResMed Common Stock4,991$206$1.0M466,256
2026-08-07Option exercise/conversionResMed Common Stock Options4,991——14,975

Key Dates

DateDescription
2026-08-07Option exercise/conversion (4,991 shares)
2026-08-07Open-market sale (4,991 shares)
2026-08-07Option exercise/conversion (4,991 shares)

Keywords

insider transaction, Form 4, RMD, RESMED INC, bearish, Michael J. Farrell

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.